Overview: Nicotine and Cotinine TestIntroduction: The Nicotine and Cotinine Test measures nicotine and cotinine to diagnose tobacco use, causing heart or lung issues. Aligned with 2023 CDC guidelines, it uses biochemistry methods for high specificity, supporting toxicology screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in toxicology for patients with suspected tobacco exposure.
Other Names: Nicotine/Cotinine Assay, Tobacco Use Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: Nicotine and cotinine testing began in the 1980s with tobacco research. Biochemical methods improved in the 2000s, enhancing detection sensitivity.
Purpose: Measures nicotine and cotinine to diagnose tobacco use, guides treatment, and evaluates patients with heart or lung issues.
Test Parameters: 1. Nicotine and Cotinine Levels
Pretest Condition: No fasting required. Collect urine, serum, plasma, or saliva. Report history of heart issues, lung issues, or tobacco use.
Specimen: Urine (sterile container, 5-20 mL), Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document heart issues, lung issues, smoking history, or exposure to secondhand smoke. Include current medications, especially smoking cessation aids.
Consent: Written consent required, detailing the tests purpose, tobacco use implications, and risks of sample collection.
Procedural Considerations: Uses biochemistry methods (e.g., gas chromatography-mass spectrometry) to measure nicotine and cotinine in specimens. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for tobacco use diagnosis.
Factors Affecting Result Accuracy: Contamination, improper sample storage, or low drug levels can affect results. Sample quality impacts sensitivity.
Clinical Significance: Elevated nicotine or cotinine confirms tobacco use, guiding smoking cessation programs. Negative results may require further exposure assessment.
Specialist Consultation: Consult a pulmonologist or cardiologist for result interpretation and treatment planning.
Additional Supporting Tests: Carbon monoxide testing, spirometry, or cardiac biomarkers to confirm tobacco-related health issues.
Test Limitations: Detection window varies by specimen; clinical correlation is needed. Secondhand smoke may cause low-level positives.
References: CDC Tobacco Guidelines, 2023; Nicotine & Tobacco Research, Benowitz NL, 2022.
